Notoginsenoside R1 Attenuates Experimental Inflammatory Bowel Disease via Pregnane X Receptor Activation

Jingjing Zhang, Lili Ding, Baocan Wang, Gaiyan Ren, Aning Sun, Chao Deng, Xiaohui Wei, Sridhar Mani, Zhengtao Wang and Wei Dou

Shanghai Key Laboratory of Complex Prescription and MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, China (J.Z., L.D., G.R., A.S., C. D., X.W., Z.W., W.D.); Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China (B.W.); Departments of Medicine and Genetics, Albert Einstein College of Medicine, NY, USA (S.M.).
Running title page

a) Running title: Notoginsenoside R1 Attenuates Experimental IBD via PXR.

b) Address Correspondence to: Zhengtao Wang (Email: wangzht@shutcm.edu.cn) and Wei Dou (Email: vivi.dou@yahoo.com), Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Room 5301, Building 5, 1200 Cailun Road, Shanghai 201203, China. Tel: 86-21-51322498, Fax: 86-21-51322519

c) The number of text pages: 15

The number of tables: 1

The number of figures: 7

The number of references: 40

Words in the Abstract: 227

Words in the Introduction: 557

Words in the Discussion: 944

d) Abbreviations:

CD, Crohn’s disease; COX2, cyclooxygenase 2; CYPs, cytochromes P450; DSS, dextran sulfate sodium; ELISA, enzyme-linked immunosorbent assay; GI, gastrointestinal; GSTs, glutathione S-transferases; IBD, inflammatory bowel disease; ICAM-1, intercellular adhesion molecule-1; interferon-gamma, IFNγ; IkBα, IκB-α; IKK, IκB kinase; IL-1α/1β/2/6/15, interleukin 1α/1β/2/6/15; iNOS, inducible NO
synthase; LBD, ligand-binding domain; LPS, lipopolysaccharide; MCP-1, monocyte chemotactic protein-1; MDR1, multidrug resistance protein 1; MPO, myeloperoxidase; MRP2, multidrug resistance protein 2; NF-κB, nuclear factor-kappa B; OATP2, organic anion transporting polypeptide 2; PBS, phosphate buffer saline; PCN, pregnenolone-16α-carbonitrile; PXR, pregnane X receptor; qRT-PCR, quantitative reverse transcription polymerase chain reaction; R1, notoginsenoside R1; RXR, retinoid X receptor; TNBS, trinitrobenzene sulfonic acid; TNF-α, tumor necrosis factor-α; TR-FRET, time-resolved fluorescence resonance energy transfer; UC, ulcerative colitis; UGTs, UDP-glucuronosyltransferases

e) The recommended section assignment to guide the paper:

- Gastrointestinal, Hepatic, Pulmonary, and Renal
ABSTRACT

Notoginsenoside R1 (R1) is the main bioactive component in Panax notoginseng, an old herb medicine widely used in Asian countries in the treatment of microcirculatory diseases. However, little is known about the effect of R1 on inflammatory bowel disease (IBD). The present study demonstrated that R1 alleviated the severity of dextran sulfate sodium (DSS)-induced colitis in mice through decreasing the activity of myeloperoxidase (MPO), the production of cytokines, the expression of pro-inflammatory genes, and the phosphorylation of Ikappa B (IkB) kinase (IKK), IkBa, and p65 in the colon. Further studies indicated that R1 dose-dependently activated human/mouse pregnane X receptor (PXR), a known target for decreasing inflammation in IBD, and upregulated the expression of genes involved in xenobiotic metabolism in colorectal cells and colon. Ligand pocket-filling Mutant (S247W/C284W or S247W/C284W/S208W) of the human PXR abrogated the effect of R1 on PXR activation. Time-resolved fluorescence resonance energy transfer (TR-FRET) PXR competitive binding assay confirmed R1 (ligand) binding affinity. In addition, PXR overexpression inhibited nuclear factor-kappa B (NF-κB)-luciferase activity, which was potentiated by R1 treatment. PXR knockdown by siRNA demonstrated the necessity of PXR in R1-induced upregulation of the expression of xenobiotic-metabolizing enzymes and downregulation of NF-κB activity. Finally, the anti-inflammatory effect of R1 was confirmed in trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice. These findings suggest that R1 attenuates experimental IBD possibly via the activation of intestinal PXR signaling.
Introduction

Inflammatory bowel disease (IBD), which includes ulcerative colitis (UC) and Crohn’s disease (CD), is a chronic inflammatory condition of the gastrointestinal (GI) tract. UC is limited to the colon, whereas CD can affect any part of the GI tract from the mouth to the anus (Baumgart and Sandborn, 2007; Gupta et al., 2013). Conventional therapeutics for IBD have been associated with multiple adverse effects. New biologic therapies, including tumor necrosis factor (TNF)-α antagonists (e.g. infliximab, adalimumab and golimumab) and integrin antagonists (e.g. vedolizumab and natalizumab), have profoundly influenced the management of IBD patients. However, there remain concerns about their potential side effects, tolerability and high costs (Jobin, 2010; Gilroy and Allen, 2014).

Pregnane X receptor (PXR, NR1I2), one of the members of the nuclear receptor superfamily, is a xenobiotic/metabolic sensor that regulates the expression of drug-metabolizing enzymes and transporters involved in the clearance of many xenobiotic chemicals (Mani et al., 2013; Smutny et al., 2013). PXR has a bulky and flexible ligand-binding pocket that enables this receptor to accommodate structurally diverse ligands, including prescription drugs, natural products, dietary supplements, environmental pollutants, endogenous hormones and bile acids (Zhang et al., 2008; Cheng et al., 2012). Ligand-activated PXR regulates the expression of a battery of genes, including phase I metabolic enzymes (cytochrome P450 (CYP) 2B6, CYP2B9, CYP2C8, CYP2C9, CYP3A4 and CYP3A7)), phase II metabolic enzymes (glutathione S-transferases (GSTs), UDP-glucuronosyltransferases (UGTs) and
sulfotransferases (SULTs)) and transporters (multidrug resistance protein 1 (MDR1), MDR2, multidrug resistance-associated protein 2 (MRP2) and the organic anion transporter polypeptide 2 (OATP2)). These enzymes and transporters are capable of recognizing a variety of xenobiotics to promote their clearance/detoxification, which is thought to be critical for maintaining intestinal barrier integrity (Zhang et al., 2008; Mencarelli et al., 2010). Indeed, disruption of the intestinal barrier function is linked to IBD. Gene analysis studies have indicated that the mRNA expression of PXR and MDR1 is significantly reduced in the colons of UC patients (Langmann et al., 2004). Others and we have demonstrated that PXR activation inhibits nuclear factor-kappa B (NF-κB) pathway and alleviates the severity of experimental IBD (Cheng et al., 2010; Dou et al., 2012). In dextran sodium sulfate (DSS)-induced IBD model, administration of pregnenolone-16α-carbonitrile (PCN), a rodent-specific PXR ligand, attenuates development of colitis through decreasing the expression of NF-κB target genes (monocyte chemotactic protein-1 (MCP-1), inducible NO synthase (iNOS), interleukin (IL)-1β, IL-6 and tumor necrosis factor-α (TNF-α)) and increasing the expression of phase II enzymes (GSTa1, GSTm1 and GSTt1) and transporters (MDR1a and MRP2) (Shah et al., 2007). Thus, Targeted activation of PXR in recent years has become a therapeutic strategy for IBD (Cheng et al., 2010; Mencarelli et al., 2011).

Notoginsenoside R1 (R1) is a characteristic constituent of Radix notoginseng, which is a well-known herbal medicine widely used in Asian countries for treating microcirculatory disturbance-related diseases, such as cardiovascular disease, cerebral
vascular disease and liver dysfunction (Sun et al., 2007; Geng et al., 2010; Fan et al., 2012). R1 has multiple pharmacological activities, including cardioprotective, neuroprotective, anti-inflammatory and anti-cancer effects (Wang et al., 2009; Sun et al., 2013; Meng et al., 2014). However, thus far, no study has reported the effect of R1 on IBD. Therefore, in the current study, we utilized in vitro and in vivo models to investigate the effects of R1 on IBD and to uncover the possible underlying mechanisms mediated through PXR activation.

**Materials and Methods**

Cell lines, reagents, semi-quantitative and real-time quantitative polymerase chain reaction (qPCR), western blot analysis, PXR-mediated NF-κB repression reporter assay, gene silencing, and time-resolved fluorescence resonance energy transfer (TR-FRET) assay details are mentioned in **Supplemental Methods**.

**Mice.** Eight-week-old female C57BL/6 mice (20 ± 2 g) were obtained from the Shanghai Laboratory Animal Center and were housed in cages at room temperature (25 ± 2°C) with a 12-h light/dark cycle. Standard mouse chow pellets and water were available ad libitum. The experiments were approved by the Animal Ethics Committee of Shanghai University of Traditional Chinese Medicine.

**DSS and Trinitrobenzene Sulfonic Acid (TNBS) Colitis Models in Mice.** DSS or TNBS colitis was induced in mice as described previously (Dou et al., 2012; Dou et al., 2013b). In brief, 4% (w/v) DSS (MW 36-50 kDa, MP Biomedicals, Solon, OH) was administered in the drinking water (tap water) for 7 days while control mice
received tap water only (n=10 mice in each group). In the TNBS model, food (but not water) was withdrawn overnight prior to TNBS (Sigma-Aldrich, MO, USA) administration. Colitis was induced by slowly and continuously intrarectal administration of a 0.1 ml of 50% ethanol solution containing 2.5 mg TNBS. Solvent alone (0.1 ml of 50% ethanol) was administered in control group. Mice received a daily gavage of R1 (25 mg/kg) in 0.5% methylcellulose from day 1 to day 7. R1 dosage was selected based on the results of a previous report in which 25 mg/kg of R1 pretreatment blocked NF-κB activation and the subsequent myocardial inflammation and apoptotic responses in endotoxemic mice (Sun et al., 2013). Mice IBD studies were repeated again for independent confirmation of the initial data.

**Assessment of Colitis.** The severity of diarrhea was monitored throughout the experimental period. The total length of the colon was measured after sacrifice of the mice under anesthesia. The distal colon was fixed in 10% buffered formalin, embedded in paraffin and processed for routine hematoxylin and eosin (H&E) staining of sections. Histological scoring was performed in a blinded fashion by two pathologists to obtain a combined score of inflammatory cell infiltration (score 0–3) and tissue damage (score 0–3) as described previously (Dou et al., 2013b).

**Wild-type/Mutant PXR Transactivation Reporter Assays.** 1×10⁶ HT-29 cells in 100 µl transfection buffer (Cell Line Nucleofector Kit V, Lonza AG, MD) were electroporated using the program W-017 according to the manufacturer’s recommendation (Lonza Nucleofector II instrument, Amaxa Biosystems, MD). For the PXR wild-type transactivation assay, the cells were transfected with 1 µg
CYP3A4-luciferase reporter combined with 0.1 µg pRL-TK, and 0.5 µg the plasmid expressing wild-type human PXR (pSG5-hPXR) or wild-type mouse PXR (pSG5-mPXR), as shown in schematic diagrams (Fig. 3B). For the PXR mutant transactivation assay, the cells were transfected with 1 µg MRP2-luciferase reporter combined with 0.1 µg pRL-TK, and 0.5 µg plasmid expressing the wild-type hPXR or the hPXR double mutant (S247W/C284W) or the hPXR triple mutant (S247W/C284W/S208W), as shown in schematic diagrams (Fig. 6A). For detailed plasmids information, referred to our previous reports (Wang et al. 2008; Venkatesh et al. 2011). For wild-type PXR transactivation assay, the cells were treated with R1 (0, 1, 10 or 25 µM) or rifampicin (10 µM, for hPXR transactivation) or PCN (10 µM, for mPXR transactivation) for 24 h. For mutant PXR transactivation assay, the cells were treated with R1 (0 or 25 µM) or rifampicin (10 µM) for 24 h. The luciferase activity of the cell extracts was measured and expressed as the fold induction compared with that of the control cells as described (Dou et al., 2012).

**Measurement of Cytokines.** Colon segments were homogenized in ice-cold PBS. The homogenates were centrifuged at 3,000 g for 10 min and the supernatants were assayed for the determination of levels of TNF-α and IL-6 as described previously (Dou et al., 2013α). The level of each cytokine was evaluated using ELISA kits according to the manufacturer’s protocols (R&D systems, Minneapolis, MN, USA) and the results are expressed in pg/mg of protein in each sample.

**Myeloperoxidase (MPO) Assay.** Tissue MPO activity, which is linearly related to neutrophil infiltration in inflamed tissue, was assayed to monitor the degree of
inflammation. MPO activity in colon tissues was measured as previously described (Zhang et al., 2014) and the values were expressed as units/mg of protein.

**Statistical Analysis.** All of the data are expressed as the mean values ± SD. The differences between the groups were analyzed using one-way analysis of variance (ANOVA) followed by the least significant difference (LSD) post-hoc test. The statistical analyses were performed using the SPSS 16.0 software package. The value of p < 0.05 was considered statistically significant.

**Results**

**R1 Ameliorated DSS-induced Colitis.** The DSS-induced colitis model is a well-established chemical IBD model with clinical features resembling human UC (Neurath and Travis, 2012). R1 treatment significantly ameliorated the DSS-induced loss of body weight, bloody diarrhea, colon shortening and histological damage (Fig. 1). The activity of MPO as well as the levels of TNF-α and IL-6 were markedly reduced by R1 treatment (Table 1). In addition, none of the mice that received R1 alone exhibited loss of body weight, diarrhea, colon shortening or mucosal disruption at any point during the study.

**R1 Inhibited NF-κB Activation and Downregulated NF-κB Target Gene Expression.** Intestinal NF-κB activation plays a central role in the pathogenesis of IBD (Atreya et al., 2008). Major steps for NF-κB activation involve the activation of IκB kinase (IKK)-α/β, which is followed by IκBα degradation and the subsequent p65/p50 nuclear translocation (Manzoor and Koh, 2012). Using western blot analysis,
we observed a phosphorylation/activation of IKK-α/β and p65 in the colonic tissue of DSS-treated mice (Fig. 2A). IκBα phosphorylation and degradation were induced in mice with DSS-induced colitis. In contrast, administration of R1 obviously reduced the expression of p-p65 and p-IKK-α/β in DSS-induced colitis, and the phosphorylation/degradation of IκBα was repressed too. To determine the effect of R1 on the expression of NF-κB signaling genes, several pro-inflammatory cytokines and chemokines in the colon were evaluated using quantitative reverse transcription PCR (qRT-PCR) analysis. The increase in the levels of inflammatory mediators (intercellular adhesion molecule-1 (ICAM-1), cyclooxygenase 2 (COX2), TNF-α, interferon-gamma (IFNγ), iNOS, MCP-1, IL-1α, IL-1β, IL-2 and IL-6)) after DSS treatment dramatically decreased in the mice that received R1 treatment (Fig. 2B).

Next, we investigated whether R1 affects the expression of NF-κB target genes in RAW264.7 mouse macrophage cells using semi-quantitative RT-PCR. RAW 264.7 macrophage cell line is a well-established model system for inflammatory studies (Wu et al., 2011). In accordance with in vivo data, R1 treatment obviously decreased the expression of iNOS, ICAM-1, MCP-1, COX2, IFNγ, TNF-α and IL-15 in lipopolysaccharide (LPS)-stimulated RAW 264.7 cells (Fig. 3A).

**R1 Activated both Human and Mouse Wild-type PXR.** In transient transfection gene reporter assays, R1 increased human or mouse PXR-mediated CYP3A4 promoter transcription in a concentration-dependent manner (Fig. 3B). In addition, rifampicin and PCN significantly activated human and mouse PXR, respectively.

**R1 Inhibited NF-κB Activity in a PXR-dependent Manner.** To determine
whether activation of PXR plays a direct role in the NF-κB repression by R1, a transient transfection reporter assay was performed. HT-29 cells have low or undetectable levels of constitutive human PXR expression (Dou et al., 2014). In cells transfected with the NF-κB-luciferase reporter and the PXR mock, treatment with the known NF-κB pathway activator TNF-α led to increased NF-κB activity; however, R1 had no effect on NF-κB activity in the absence of human PXR expression (Fig. 4A). In cells transfected with the NF-κB-luciferase reporter and the human PXR expression vector, TNF-α-stimulated NF-κB activity was significantly inhibited by R1 in the presence of human PXR expression. To further demonstrate that PXR is specifically involved in the suppression of NF-κB by R1, PXR siRNA transfection was conducted in above HT-29 cells, which had been previously transfected with the NF-κB-luciferase reporter and the human PXR expression plasmid. As expected, the regulatory effect of R1 on TNF-α-stimulated NF-κB activity was abrogated (Fig. 4B).

**R1 Upregulated the Expression of Xenobiotic-metabolizing Genes in vitro and in vivo.** PXR target genes are critical components in the intestinal barrier function against xenobiotics and bacteria (Langmann et al., 2004; Mencarelli et al., 2010). In the current study, we observed a robust upregulation of the expression of CYP3A11, UGT1A1 and MDR1a in the colons of mice that received 7 days of R1 treatment (Fig. 5A). Consistent with the *in vivo* results, an increase in the expression of CYP3A4, UGT1A1 and MDR1a was observed in LS174T cells exposed to R1 treatment (Fig. 5B).

**R1 Upregulated the Expression of Xenobiotic-metabolizing Genes in a
PXR-dependent Manner. To explore the mechanistic involvement of PXR in the modulation of the genes responsible for xenobiotic metabolism, the human PXR gene expression in LS174T colon adenocarcinoma cells was reduced by PXR siRNA transfection. As shown in Fig. 5C, the treatment of LS174T cells with an anti-PXR siRNA significantly decreased the expression of PXR. In addition, the regulatory effect of R1 on the mRNA expression of UGT1A1 and MDR1a was abrogated in cells transfected with anti-PXR siRNA.

Ligand Pocket-filling Mutants of Human PXR Abolished R1-mediated PXR Activation. To provide evidence that R1 indeed binds to the ligand-binding pocket of the human PXR and subsequently activates the transcription of MRP2 promoter, we performed a transient transactivation reporter assay using the double-mutant (S247W/C284W) and triple-mutant (S247W/C284W/S208W) constructs of the human PXR ligand-binding pocket. The results showed that the double or triple mutants of PXR led to ligand-independent constitutive activation of the MRP2 promoter (Fig. 6A), which is consistent with the results of previous reports (Wang et al., 2008; Venkaresh et al., 2011). In addition, both rifampicin and R1 activated the wild-type human PXR, whereas none of them activated either double or triple mutant.

Confirmation of the PXR-binding Properties by TR-FRET Assay. To confirm the direct binding of R1 to the ligand-binding pocket of the human PXR, a LanthaScreen TR-FRET PXR competitive binding assay was performed. R1 concentration-dependently decreased the TR-FRET emission ratio (Fig. 6B). In addition, both rifampicin and SR12813 significantly decreased the TR-FRET ratio.
R1 Treatment Attenuated the Severity of TNBS-induced Colitis. Next, to determine whether R1 also had a therapeutic effect on another chemical model of colitis, we tested its effects on some parameters of colitis induced by the hapten TNBS, which constitutes a CD model (Neurath and Travis, 2012). The rectal administration of TNBS led to ulcers in the rectum, increased MPO activity, and upregulated TNF-α and IL-6 levels (Fig. 7, Table 1). Oral R1 administration significantly improved these parameters and ameliorated the histological pathology. No significant changes were observed in vehicle and R1-treated normal mice.

Discussion

Chemically induced colitis models have been developed and extensively used to elucidate the pathogenic mechanisms of IBD. One of the most widely used experimental models is developed by treating animals with DSS in drinking water for 6-10 days. The resulting inflammation generally affects the mucosal lining of the intestinal wall, with disease features that resemble human UC (Neurath and Travis, 2012). In the current study, colitis was induced by DSS treatment, and the exposure of mice to R1 ameliorated the disease hallmarks, such as body weight loss, bloody diarrhea, colon shortening and histological damage. To assess whether R1 would have similar effects on another chemical model of colitis, we tested its effects on some parameters of colitis induced by TNBS, which constitutes a CD model of transmucosal inflammation (Neurath and Travis, 2012). The results showed that the
rectal administration of TNBS dissolved in ethanol induced severe colitis in mice and that R1 treatment reduced the extents of histological damage and colon shortening. Since no report about the effect of R1 on UC or CD has been available, our findings are unique in establishing the role of R1 in ameliorating the UC- or CD-like features in murine models of IBD. Notably, none of the mice that received R1 alone exhibited apparent body weight loss, diarrhea, colon shortening or mucosal disruption throughout this study, indicating the relative safety of the R1 treatment.

Recent studies have shown that PXR is involved in the pathogenesis of IBD (Cheng et al., 2010; Cheng et al., 2012). Loss of PXR function has been associated with intestinal inflammation in animal models (Cheng et al., 2010; Dou et al., 2012). Gene expression profiling of the colon tissues from UC and CD patients demonstrated a significant inhibition of PXR and its target genes (Shah et al., 2007). Several polymorphisms in the PXR locus have been proved to be associated with an increased susceptibility to IBD (Langmann et al., 2004; Dring et al., 2006). PXR has a bulky and flexible ligand-binding pocket, which enables it to accommodate a structurally promiscuous library of ligands (Tolson and Wang, 2010). Upon activation, PXR heterodimerizes with retinoid X receptor (RXR) and binds to the response elements of PXR target genes. In the present study, we found that R1 dose-dependently activated human PXR, which is likely due to binding to the LBD of PXR. It has long been known that ligand-activated PXR regulates the expression of biotransformation enzymes and transport proteins involved in the metabolism and elimination of harmful substances from the body (Langmann et al., 2004). The detoxification properties of
PXR and its target genes are necessary to maintain the integrity of the intestinal epithelial barrier (Shah et al., 2007). In this study, we found that R1 upregulated the expression of CYP3A, UGT1A1 and MDR1a, and this effect was mediated by PXR. It was recently reported that natural compound curcumin decreases the susceptibility of MDR1a-/- mice to spontaneous colonic inflammation through PXR activation (Nones et al., 2009). Our results support to the notion that enhanced intestinal epithelial integrity via PXR-mediated induction of xenobiotic detoxification might contribute to the observed anti-inflammatory effects of R1, but further studies are required.

Although the exact etiology of IBD remains unknown, it has been generally accepted that the increase of pro-inflammatory cytokines such as IL-1β and TNF-α within colonic tissues plays an important role in the pathogenesis of IBD (Shah et al., 2007). Also, it has been demonstrated that all these pro-inflammatory cytokine genes are transcriptionally regulated by NF-κB (Tak and Firestein, 2001). NF-κB can be activated by diverse stimuli including pro-inflammatory cytokines, microbes and microbial products, and oxidative stress (Liu and Wang, 2011). Activation of NF-κB leads to the gene expression of pro-inflammatory cytokines and chemokines involved in the pathogenesis of IBD. The most abundant form of NF-κB in cells is the p50/p65 heterodimer, which is normally sequestered in the cytoplasm by binding to the inhibitory protein IκBα. Following various stimuli, IκBα is rapidly phosphorylated by IKK, ubiquitinated and subsequently degraded by proteasome, allowing NF-κB p50/p65 to translocate to the nucleus where it drives the expression of target genes.
In our study, we found that R1 treatment not only decreased the proteins of p-IKK-α/β, p-IκBα and p-p65, but also downregulated the pro-inflammatory genes expression, and reduced the activity of MPO and the accumulation of TNF-α and IL-6. Further studies indicated that R1 decreased the activity of NF-κB in a PXR-dependent manner. In fact, recent molecular and pharmacological studies have revealed a mutual suppression between PXR and the NF-κB signaling pathway (Xie and Tian, 2006; Wahli, 2008). High NF-κB activity inhibits the activation of PXR (Gu et al., 2006), whereas PXR activation suppresses the activity of NF-κB and the expression of its target genes (Zhou et al., 2006).

IBD is associated with a considerable reduction in the quality of life of the patients, and currently no curative treatment is available (van der Marel et al., 2011; Gupta et al., 2013). The use of medicinal plants or their active components is becoming an increasingly attractive approach for the management of IBD (Shin et al., 2009; Zhang et al., 2014). In the present study, as a part of our on-going screening program to evaluate the anti-inflammatory potentials of natural compounds (Dou et al., 2013a, Zhang et al., 2014), we investigated the anti-inflammatory effects of R1 on DSS- or TNBS-induced colitis. To our knowledge, for the first time, the present study demonstrates a beneficial effect of R1 on chemically induced IBD (UC-like or CD-like). The anti-inflammatory effect of R1 might be associated with the activation of PXR signaling. The results support further evaluation of the therapeutic potential of R1 in human IBD.
Authorship Contributions

Participated in research design: Z Wang and W Dou.

Conducted experiments: J Zhang, L Ding, G Ren and C Deng.

Materials support: B Wang and X Wei.

Data analysis: J Zhang and A Sun.

Wrote the manuscript: S Mani and W Dou.

Conflict of interest

The authors state no conflict of interest.
References


van der Marel S, Majowicz A, van Deventer S, Petry H, Hommes DW, Ferreira V.
(2011) Gene and cell therapy based treatment strategies for inflammatory bowel

in vitro characterization of a first-in-class novel azole analog that targets

Antiproliferative effects of different plant parts of Panax notoginseng on SW480

phytoestrogen coumestrol is a naturally occurring antagonist of the human


Wu TY, Khor TO, Saw CL, Loh SC, Chen AI, Lim SS et al. (2011)
Anti-inflammatory/Anti-oxidative stress activities and differential regulation of
Nrf2-mediated genes by non-polar fractions of tea Chrysanthemum zawadskii

Xie W, Tian Y. (2006) Xenobiotic receptor meets NF-kappaB, a collision in the small


Footnotes

This work was supported by National Natural Science Foundation of China [81273572, U1032604]; Natural Science Foundation of Shanghai [12ZR1431400]; Innovation Program of Shanghai Municipal Education Commission [13YZ043]; National Institutes of Health Grant [RO1CA127231]; Damon Runyon Foundation Clinical Investigator Award [CI 1502]. Address Correspondence to: Zhengtao Wang (Email: wangzht@hotmail.com) and Wei Dou (Email: vivi.dou@yahoo.com), Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Room 5301, Building 5, 1200 Cailun Road, Shanghai 201203, China. Tel: 86-21-51322498, Fax: 86-21-51322519.
Legends for Figures

**Figure 1.** R1 attenuated DSS-induced colitis in mice. (A) Changes in body weight following DSS induction of colitis. The data are plotted as a percentage of the original body weight. (B) The occurrence of bloody diarrhea. The data are plotted as a percentage of the total mice that had bloody diarrhea at different time points of DSS treatment. (C) Macroscopic observation of colon shortening. (D) Assessment of colon shortening. (E) Representative H&E-stained colon sections (magnification 200×). (F) Histology scoring for H&E-stained colon sections. The data are expressed as the mean values ± SD of n = 10 mice in each group. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. the DSS-treated group.

**Figure 2.** The effects of R1 on NF-κB activation and target genes expression *in vivo*. (A) Total protein (40 μg) was extracted from colon samples (n = 6 per group) and examined for the expression of p-IKK-α/β, p-p65, p-IκBα, IκBα and β-actin by western blot analysis. The results are representative of three independent experiments. (B) The levels of the expression of NF-κB target genes in colon samples isolated from mice (n = 6 per group) were determined using qRT-PCR. The levels of expression are normalized to that of β-actin, and each bar represents the mean value ± SD of two independent experiments performed using samples in triplicate. * p < 0.05, ** p < 0.01 vs. DSS-treated group.

**Figure 3.** The Effects of R1 on NF-κB target gene expression *in vitro* and on PXR
activation. (A) The levels of the mRNA expression of NF-κB target genes in LPS-stimulated RAW264.7 macrophages following R1 treatment (0 and 25 μM, for 48 h) were detected by semi-quantitative RT-PCR. The results are representative of three independent experiments. (B) Wild-type h/mPXR transactivation reporter assay. Transient transactivation assays were performed in HT-29 cells cotransfected with CYP3A4-reporter, pRL-TK and pSG5-hPXR or pSG5-mPXR. The cells were incubated with R1 (0, 1, 10 or 25 μM) or rifampicin (10 μM, for hPXR) or PCN (10 μM, for mPXR) for 24 h. A standard dual-luciferase assay of the cell lysates was performed, and the results are expressed as the fold induction compared with that of the control cells. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle-treated cells.

Figure 4. Role for PXR in R1-mediated NF-κB luciferase inhibition. (A) HT-29 cells were electroporated with the pGL4.32[luc2P/NF-κB-RE/Hygro] reporter combined with pRL-TK and pSG5-hPXR or pSG5-mock. PXR overexpression was verified by western blot analysis (left panel). After transfection, the cells were treated with TNF-α (20 ng/ml) alone or in combination with R1 (25 μM) for 24 h. A standard dual-luciferase activity of the cell lysates was measured and the results are expressed as the fold induction compared with that of the control cells (designated as 1). The results are presented as the mean values ± SD of three independent experiments. * p < 0.05 vs. hPXR-transfected cells treated with TNF-α alone. (B) The human PXR gene was silenced by PXR siRNA transfection in above HT-29 cells previously transfected with the pGL4.32[luc2P/NF-κB-RE/Hygro] reporter and the human PXR expression
plasmid pSG5-hPXR. The depletion of PXR by siRNA transfection in HT-29 cells was verified using western blot (left panel). After transfection, the cells were treated with TNF-α (20 ng/ml) alone or cotreated with R1 (25 μM) for 24 h. A standard dual luciferase assay of the cell lysates was performed. The results are presented as the mean values ± SD of three independent experiments. * p < 0.05 vs. control siRNA transfection samples treated with TNF-α alone.

**Figure 5.** The role of PXR in the R1-mediated upregulation of PXR target genes. qRT-PCR was performed to assess the mRNA expression of CYP3A11 (CYP3A4 for human), UGT1A1 and MDR1a in colon samples isolated from mice (n = 6 per group) orally fed 25 mg/kg R1 for 7 days (A) or in LS174T cells (n = 3) treated with 25 μM R1 for 48 h (B). The levels of expression are normalized to that of β-actin, and each bar represents the mean value ± SD of two independent experiments performed using samples in triplicate. * p < 0.05, ** p < 0.01, *** p < 0.001 vs. vehicle-treated group. (C) The depletion of PXR in LS174T cells using siRNA transfection was verified using western blot (top panel). The mRNA expression of UGT1A1 and MDR1a was assessed using qRT-PCR (bottom panel). The results are expressed as the mean values ± SD from triplicate samples of two independent experiments. *** p < 0.001 vs. vehicle-treated cells transfected with control siRNA.

**Figure 6.** Effects of R1 on the transactivation of PXR mutants and TR-FRET assay. (A) Transient transcription assays were performed in HT-29 cells cotransfected with
MRP2-luciferase reporter, pRL-TK, and the wild-type hPXR (pSG5-hPXR) or the hPXR double mutant (S247W/C284W) or the hPXR triple mutant (S247W/C284W/S208W). The cells were treated with R1 (0 and 25 μM) or rifampicin (10 μM) for 24 h. Luciferase activities were measured and the results are expressed as the fold induction compared with that of the control cells. The results are presented as the mean values ± SD of three independent experiments. ** p < 0.01, *** p < 0.001 vs. vehicle-treated cells. (B) The LanthaScreen TR-FRET competitive binding assay was used to evaluate the ability of R1 (0, 12.5, 25, 50 and 100 μM) to interact with PXR in vitro. Rifampicin (10 μM) and SR12813 (1 μM) were included as positive control PXR ligands. The TR-FRET ratio was calculated by dividing the emission signal at 520 nm by that at 495 nm. The results are expressed as the mean values ± SD from a representative experiment performed in quadruplicate. * p < 0.05, ** p < 0.01 vs. vehicle-treated cells.

Figure 7. R1 attenuated TNBS-induced colitis in mice. (A) Macroscopic observation and assessment of colon shortening (n = 10). (B) Representative H&E-stained colon sections (magnification 200×) and histology scores. The results are expressed as the mean values ± SD of n = 10 mice in each group. * p < 0.05, ** p < 0.01 vs. TNBS-treated group.
Table 1. Effects of R1 on the activity of MPO and the levels of TNF-α and IL-6 in DSS- or TNBS-induced colitis mice.

<table>
<thead>
<tr>
<th>Group</th>
<th>DSS</th>
<th>TNBS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>TNF-α (pg/mg pr.)</td>
<td>IL-6 (pg/mg pr.)</td>
</tr>
<tr>
<td>Vehicle</td>
<td>14.6 ± 1.7</td>
<td>28.9 ± 2.3</td>
</tr>
<tr>
<td>R1</td>
<td>16.96 ± 1.1</td>
<td>23.79 ± 4.1</td>
</tr>
<tr>
<td>DSS/TNBS</td>
<td>127.4 ± 8.5</td>
<td>214.3 ± 17.9</td>
</tr>
<tr>
<td>DSS/TNBS+R1</td>
<td>61.5 ± 3.9 **</td>
<td>164.2 ± 16.6 *</td>
</tr>
</tbody>
</table>

Colon segments from mice (n = 6 per group) were excised and homogenized. The supernatants were assayed for the determination of the activity of MPO and the levels of TNF-α and IL-6 as described in the Materials and Methods. Values are expressed as the mean ± SD. * p < 0.05, **P < 0.01 vs. DSS- or TNBS-treated group.
Figure 3

A

RAW264.7 cells

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>R1</th>
<th>Vehicle</th>
<th>R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>iNOS</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>iCAM-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCP-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COX2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TNF-α</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IFN-γ</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-15</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

B

HT-29

RXR  PXR  luciferase
cyp3A4

<table>
<thead>
<tr>
<th></th>
<th>hPXR</th>
<th>mPXR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rif 0 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rif 1 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rif 10 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rif 25 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN 0 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN 1 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN 10 μM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN 25 μM</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Fold luciferase induction

<table>
<thead>
<tr>
<th></th>
<th>R1 (μM)</th>
<th>R1 (μM)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rif</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PCN</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Figure 5

A

Colon

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP3A11</td>
<td></td>
<td>***</td>
</tr>
<tr>
<td>MDR1a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>UGT1A1</td>
<td></td>
<td>***</td>
</tr>
</tbody>
</table>

B

LS174T

<table>
<thead>
<tr>
<th></th>
<th>Vehicle</th>
<th>R1</th>
</tr>
</thead>
<tbody>
<tr>
<td>CYP3A4</td>
<td></td>
<td>*</td>
</tr>
<tr>
<td>MDR1a</td>
<td></td>
<td>**</td>
</tr>
<tr>
<td>UGT1A1</td>
<td></td>
<td>*</td>
</tr>
</tbody>
</table>

C

LS174T

siRNA

<table>
<thead>
<tr>
<th></th>
<th>siRNA</th>
<th>Control</th>
<th>PXR</th>
</tr>
</thead>
<tbody>
<tr>
<td>PXR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Actin</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Relative mRNA expression

<table>
<thead>
<tr>
<th></th>
<th>0 25 0 25</th>
<th>0 25 0 25</th>
</tr>
</thead>
<tbody>
<tr>
<td>UGT1A1</td>
<td>***</td>
<td></td>
</tr>
<tr>
<td>MDR1a</td>
<td></td>
<td>***</td>
</tr>
</tbody>
</table>
Figure 7

A

B

Vehicle  |  TNBS  |  TNBS+R1

Vehicle  |  R1    |  TNBS  |  TNBS+R1

Colon length (cm)

Histological score

Vehicle  |  R1    |  TNBS  |  TNBS+R1